Clofedanol

Identification

Summary

Clofedanol is an antitussive used for the symptomatic relief of acute cough caused by minor throat and bronchial irritation.

Brand Names
Biclora, Ninjacof, Poly Hist Pd, Vanacof-8
Generic Name
Clofedanol
DrugBank Accession Number
DB04837
Background

Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States.

Type
Small Molecule
Groups
Approved, Withdrawn
Structure
Thumb
Weight
Average: 289.8
Monoisotopic: 289.123341974
Chemical Formula
C17H20ClNO
Synonyms
  • Chlophedianol
  • Clofedanol
  • Clofedanolum
  • Clofedianolo

Pharmacology

Indication

Used in the treatment of dry cough.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Chlophedianol (or Clofedanol) is a centrally-acting cough suppressant. It has local anesthetic and antihistamine properties, and may have anticholinergic effects at high doses.

Mechanism of action

Suppresses the cough reflex by a direct effect on the cough center in the medulla of the brain.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Hepatic.

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AmphetamineAmphetamine may decrease the sedative and stimulatory activities of Clofedanol.
BenzphetamineBenzphetamine may decrease the sedative and stimulatory activities of Clofedanol.
Benzylpenicilloyl polylysineClofedanol may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Clofedanol.
DextroamphetamineDextroamphetamine may decrease the sedative and stimulatory activities of Clofedanol.
DiethylpropionDiethylpropion may decrease the sedative and stimulatory activities of Clofedanol.
HyoscyamineClofedanol may increase the anticholinergic activities of Hyoscyamine.
Iofetamine I-123Iofetamine I-123 may decrease the sedative and stimulatory activities of Clofedanol.
LisdexamfetamineLisdexamfetamine may decrease the sedative and stimulatory activities of Clofedanol.
MephentermineMephentermine may decrease the sedative and stimulatory activities of Clofedanol.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Avoid alcohol.
  • Take with or without food. The absorption is unaffected by food.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Chlophedianol hydrochloride69QQ58998Y511-13-7XYGSFNHCFFAJPO-UHFFFAOYSA-N
Clofedanol hydrochlorideNot AvailableNot AvailableNot applicable
International/Other Brands
Antitussin
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
UloneSyrup25 mg / 5 mLOralBausch Health, Canada Inc.1962-12-31Not applicableCanada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Abanatuss PedChlophedianol hydrochloride (25 mg/5mL) + Dexchlorpheniramine maleate (2 mg/5mL) + Pseudoephedrine hydrochloride (60 mg/5mL)SolutionOralKRAMER NOVIS2015-07-01Not applicableUS flag
Abanatuss Ped DropsChlophedianol hydrochloride (6.25 mg/1mL) + Dexchlorpheniramine maleate (0.5 mg/1mL) + Pseudoephedrine hydrochloride (15 mg/1mL)SolutionOralKRAMER NOVIS2015-08-05Not applicableUS flag
Atuss DaChlophedianol hydrochloride (12.5 mg/5mL) + Brompheniramine maleate (2 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL)LiquidOralAber Pharmaceuticals, Llc2016-02-082018-01-31US flag
Atuss DaChlophedianol hydrochloride (12.5 mg/5mL) + Brompheniramine maleate (2 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL)LiquidOralMagna Pharmceuticals, Inc.2018-11-20Not applicableUS flag
Atuss DaChlophedianol hydrochloride (12.5 mg/5mL) + Brompheniramine maleate (2 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL)LiquidOralCarwin Associates, Inc2016-10-25Not applicableUS flag
BicloraChlophedianol hydrochloride (12.5 mg/5mL) + Chlorcyclizine hydrochloride (12.5 mg/5mL)LiquidOralPhysicians Total Care, Inc.2013-01-02Not applicableUS flag
BicloraChlophedianol hydrochloride (12.5 mg/5mL) + Chlorcyclizine hydrochloride (12.5 mg/5mL)LiquidOralHawthorn Pharmaceuticals, Inc.2012-10-312014-10-23US flag
BicloraChlophedianol hydrochloride (25 mg/1) + Chlorcyclizine hydrochloride (25 mg/1)TabletOralHawthorn Pharmaceuticals, Inc.2012-11-302014-10-23US flag
biclora-DChlophedianol hydrochloride (12.5 mg/5mL) + Chlorcyclizine hydrochloride (12.5 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL)LiquidOralHawthorn Pharmaceuticals, Inc.2012-10-082014-10-23US flag
biclora-DChlophedianol hydrochloride (25 mg/1) + Chlorcyclizine hydrochloride (25 mg/1) + Pseudoephedrine hydrochloride (60 mg/1)TabletOralHawthorn Pharmaceuticals, Inc.2012-11-302014-11-30US flag

Categories

ATC Codes
R05DB10 — Clofedanol
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Chlorobenzenes / Aralkylamines / Aryl chlorides / Tertiary alcohols / 1,3-aminoalcohols / Trialkylamines / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives / Aromatic alcohols
Substituents
1,3-aminoalcohol / Alcohol / Amine / Aralkylamine / Aromatic alcohol / Aromatic homomonocyclic compound / Aryl chloride / Aryl halide / Chlorobenzene / Diphenylmethane
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
42C50P12AP
CAS number
791-35-5
InChI Key
WRCHFMBCVFFYEQ-UHFFFAOYSA-N
InChI
InChI=1S/C17H20ClNO/c1-19(2)13-12-17(20,14-8-4-3-5-9-14)15-10-6-7-11-16(15)18/h3-11,20H,12-13H2,1-2H3
IUPAC Name
1-(2-chlorophenyl)-3-(dimethylamino)-1-phenylpropan-1-ol
SMILES
CN(C)CCC(O)(C1=CC=CC=C1)C1=CC=CC=C1Cl

References

Synthesis Reference

Lorenz, R., Gosswald, R. and Henecka, H.; US. Patent 3,031,377; April 24, 1962; assigned to Farbenfabriken Bayer AG, Germany.

General References
Not Available
Human Metabolome Database
HMDB0015585
PubChem Compound
2795
PubChem Substance
46505324
ChemSpider
2693
RxNav
21254
ChEBI
135207
ChEMBL
CHEMBL1201313
Therapeutic Targets Database
DAP001080
PharmGKB
PA164748134
Drugs.com
Drugs.com Drug Page
Wikipedia
Clofedanol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionOral
SuspensionOral
Tablet, multilayerOral
TabletOral
LiquidOral
Tablet, chewableOral
SyrupOral
Solution / dropsOral
SyrupOral25 mg / 5 mL
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)120 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.0621 mg/mLALOGPS
logP3.51ALOGPS
logP3.46ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)13.18ChemAxon
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity84.94 m3·mol-1ChemAxon
Polarizability31.25 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9892
Blood Brain Barrier+0.9474
Caco-2 permeable+0.7603
P-glycoprotein substrateSubstrate0.6468
P-glycoprotein inhibitor INon-inhibitor0.6719
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterInhibitor0.5846
CYP450 2C9 substrateNon-substrate0.7596
CYP450 2D6 substrateSubstrate0.619
CYP450 3A4 substrateSubstrate0.754
CYP450 1A2 substrateNon-inhibitor0.5972
CYP450 2C9 inhibitorNon-inhibitor0.8098
CYP450 2D6 inhibitorInhibitor0.8482
CYP450 2C19 inhibitorNon-inhibitor0.7196
CYP450 3A4 inhibitorNon-inhibitor0.6746
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6213
Ames testNon AMES toxic0.8129
CarcinogenicityNon-carcinogens0.7042
BiodegradationNot ready biodegradable0.9928
Rat acute toxicity2.7383 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.755
hERG inhibition (predictor II)Inhibitor0.7948
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0pb9-9560000000-539851d74afb04d60422
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
  4. Maurer H, Pfleger K: Identification and differentiation of alkylamine antihistamines and their metabolites in urine by computerized gas chromatography-mass spectrometry. J Chromatogr. 1988 Aug 19;430(1):31-41. [Article]

Drug created on September 26, 2007 14:12 / Updated on September 28, 2021 07:54